Results 221 to 230 of about 126,534 (277)
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami +16 more
wiley +1 more source
History of glucagon-like peptide-1 receptor agonists
Radwan Darwish +2 more
doaj +1 more source
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen +7 more
wiley +1 more source
An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases
Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller +7 more
wiley +1 more source
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay +19 more
wiley +1 more source
Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2. [PDF]
Shao Q, Xiong J, Wu J, Mao J, Hu Q.
europepmc +1 more source
Abstract Aim Coronary artery calcium (CAC) scoring is observed to improve risk stratification for major adverse cardiovascular events (MACE). Semaglutide, a recently introduced anti‐obesity drug, is very effective, but wider use is limited due to high costs.
Sai Rahul Ponnana +11 more
wiley +1 more source

